Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It appears to me that the sellers have a tighter grip on those shares.
LMAO!
Triple zero is a bit of a stretch, but the "Pop" will be here soon.
One of these days one of Otiko's "Big" deals are going to come though and he sure sounded confident to state a 3 week deadline.
The question is "Are you in, or are you going to chase it when the news breaks?" Once it does, there are few shares between $.0041 and $.01 with nothing above that.
Good luck to you
Well than, sell me your shares before the price drops again, just like you said.
I'm looking to buy some shares at $.0035 today before the next run-up, anyone out there can help me out with this? Thanks in advance!
Kasten sure believes in the product, remember you bough some of that crappy stock with the worthless product.
Let's not jump the gun here, we still have 4 trading days in July. As for VitaStem working not, I suggest you spend a little money out of the vast capital gains you claim from other stocks and buy a bottle and judge for yourself if the product works, otherwise your opinion means very little to those us who have experienced the healing capacity of the drug.
Wow! That's all? Thank God it wasn't in the Billions like many other penny stock companies.
Bring it on, you can do better than that!
Progress? How about the fact that VDRM actually had a product launch last September?
For what this company is doing going forward, 17 million shares is reasonable.
What else you got?
That's all you got? Name calling and the same ole "Dilution" Scare, but thanks' for the good luck and good luck to you as well getting your money back playing the spread,
"Make or Break"/ "In or Out" now is the time to make the call...
CEO Otiko gave us a detailed preview of what's going on with VDRM and I believe he's going to pull one of these deals off.
June 25, 2018
"Our recent trip to India was a great success. I was able to personally demonstrate the effectiveness of our product and meet with several potential future partners who are interested in distributing Vitastem. We are in the process of follow up discussions with three of them, and hope to introduce Vitastem into the Indian market in the very near future.
• The process of registering Vitastem with the National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria’s equivalent to the FDA was initiated last month. Registration is expected to be finalized in July. At that time, Vage Nigeria Ltd. will pay a 50% deposit to ViaDerma in the amount of $125,000 for its initial order worth $250,000.
• Over the past several weeks I have been meeting with representatives for a South American based distributor. As per our discussions thus far, I expect to receive their initial order for Vitastem within the next few weeks. They have indicated an interest in purchasing lots of 200,000 per month. An order of that size would equal $3 million in annual revenues.
• Sales in Japan are temporarily held up while some issues are being resolved. At the customer’s request we will be changing the active ingredient of the antibiotic for their orders from tetracycline to a natural product, Manuka Honey UMF-15. Once the changes have been worked out we expect to commence a steady flow of product delivery to our Japanese distributors.
• Drug registration in the Philippines has taken much longer than originally anticipated and is not expected to be completed until later this year. We are working closely with regulators to move the process forward. • Vitastem has been available for purchase on Amazon for the past few months. In the brief time on Amazon, sales have been growing each month at a very strong rate with minimal marketing efforts to this point. May sales grew by 67%, and we anticipate being on Amazon
One of my favorite post of all times...
todd1975
Monday, 05/08/17 12:16:46 PM
Re: None
0
Post # of 38933
"I'm riding this train all the way to the top baby......I don't care how long it takes......it's only a matter of weeks and it's gonna be greeee-aaa-t"
I think you will be back on the "Long-Bus" by the July 31st. Otiko sounds very confident in closing a deal before the end of the month.
I see a lot of Up-side to this trade and little to the downside.
If he pulls it off, easy 100%-500% gain. If not, possible drop to $.0030 a 25% loss.
This a the perfect penny stock high risk play people look for when it comes to "Big Baggers".
No settlement needed, case was dismissed in January.
I agree, poor English, but I believe it was authored by a third party reporter. It looks like they paraphrased the official PR the company released earlier.
This is the first time I have heard anything about a settlement with Keough, please provide a link where you obtained this information.
Checkout some of the great reviews on the Amazon website..
www.amazon.com/Vitastem-Super-Healing-Antibiotic-Infections-associated/product-reviews/B076V2RM46/ref=cm_cr_othr_d_paging_btm_2?ie=UTF8&reviewerType=all_reviews&sortBy=recent&filterByStar=all_stars&pageNumber=2#R2VAARM92H76WF
Finally, something that works!
ByTraci J.on February 23, 2018
I've been a customer of Amazon since 2004 and this is the first time I've written a review. I've had Dyshidrotic eczema for about a year on the palm of my hand due to stress. I've had it once before that also lasted a year. Nothing has worked for me, including VERY expensive prescription steroid creams. After using Vitastem for two days, the itching and burning was gone and I saw no new eruptions. Five days later, it's almost completely gone. Vitastem was a godsend for me as the burning and itching was unbearable. This product is worth every single cent.
5.0 out of 5 stars
9 people found this helpful
Great read, sums things up here pretty good. Thank you.
Know what you own and you will be solidified in your investment decisions. I know what I, we have here in VDRM and young "Newbies" will not persuade me to sell or buy any stock, including VDRM.
Timing is everything. The time to buy VRDM for all the right reasons; Oversold to a low PPS, Many Irons in the fire and ready to be hammered out into a significant sales contract, new advertising Champaign launched and new CBD product lines developed and market tested.
Now is a great time to enter VDRM as an investment, but don't listen to me, it's just my opinion. Do your own DD.
If you knew anything about moderating a board, you would know that the editing share structure count is out of our control.
What we really need is for a couple of the $.005 bid sitters to step up and slap that Ask at $.0052 and we can move on to $.0055.
Nothing quite like a Jester to entertain us while we wait for the management to pen a big contract.
The Bulls are waking up to VDRM and soon the bears will go back into hibernation.
Go VDRM!
"Where's the beef!"
Dr. Otiko has been telling us about this deal and that deal, but where's the beef doctor? It sounds like he feels very confident that you will pen a deal very soon. I can appreciate the update, but we need more beef! No big buns, no more fillers, no more hype, just a confirmed and sign contract.
I do get the sense that a deal is near from your commitment to telling us some details of possible sales contracts and promotions, but that's all bun, we need beef to survive.
We're all getting hungry Doc!
CEI is now “Over-Sold”. Why?
Reason #1.) Just two weeks ago management reorganized the debt structure and saved themselves (us) $62M. If the outstanding share count is 10M the savings along is worth $.62 per share on top of the $.26 PPS prior to the news release.
#2.) A barrel of oil double in the past 6 months and CEI does have revenue in both the crude oil and NG markets.
#3.) Trump’s tax plan is a game changer for all corporations. That alone should double the PPS.
All of the small and marginal oil producers that survived the drop in oil prices over the last few years are all going to flourish in the coming years as the world’s economies cycle into a more prosperous phase of the economic cycle.
Just my opinion, life’s a gamble.
How would we know why the Nigerian deal has not been realized? Why don't you put on your big boy pants and call IR and ask them that question and share with us their answer.
Constructive criticism carries so much better than inflammatory rhetorical questions to the gallery.
Your wish is my command, done.
So much "Up-side" to this company at these prices, VDRM is a "No-Brainer" gamble...
A Note From The CEO
Date: June 25, 2018
Dear Shareholders & Associates of ViaDerma,
What exciting times we are in as ViaDerma continues to make big strides both domestically and internationally. As we continue such an expansion I want to ensure that you remain abreast of all developments and changes as they occur. This note is just the first of many to come as I am committing to you, our most valued shareholder to address you on a regular basis. Upon your receipt of this and every future note I encourage you to ask questions and learn more about what ViaDerma embarks upon to ensure that the union of our company, both present and future remains strong.
Since the start of 2018, ViaDerma has achieved several new milestones and I believe we are now poised to experience very significant growth in the coming months. While we feel our current trajectory is pointed upward, the last year has not been without its challenges. Fortunately, the bumps along the way have been minor in the big scheme of things, and resolvable and have only caused temporary delays in our progress. Below is a list of some of the key developments and setbacks we have experienced so far:
• Our recent trip to India was a great success. I was able to personally demonstrate the effectiveness of our product and meet with several potential future partners who are interested in distributing Vitastem. We are in the process of follow up discussions with three of them, and hope to introduce Vitastem into the Indian market in the very near future.
• The process of registering Vitastem with the National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria’s equivalent to the FDA was initiated last month. Registration is expected to be finalized in July. At that time, Vage Nigeria Ltd. will pay a 50% deposit to ViaDerma in the amount of $125,000 for its initial order worth $250,000.
• Over the past several weeks I have been meeting with representatives for a South American based distributor. As per our discussions thus far, I expect to receive their initial order for Vitastem within the next few weeks. They have indicated an interest in purchasing lots of 200,000 per month. An order of that size would equal $3 million in annual revenues.
• Sales in Japan are temporarily held up while some issues are being resolved. At the customer’s request we will be changing the active ingredient of the antibiotic for their orders from tetracycline to a natural product, Manuka Honey UMF-15. Once the changes have been worked out we expect to commence a steady flow of product delivery to our Japanese distributors.
• Drug registration in the Philippines has taken much longer than originally anticipated and is not expected to be completed until later this year. We are working closely with regulators to move the process forward.
• Vitastem has been available for purchase on Amazon for the past few months. In the brief time on Amazon, sales have been growing each month at a very strong rate with minimal marketing efforts to this point. May sales grew by 67%, and we anticipate being on Amazon
Prime in the coming weeks which should dramatically increase our sales. We will be rolling out an aggressive product marketing campaign in the near future which we expect will result in a significant increase in sales on Amazon and across other platforms.
• We have recently produced the first in a series of commercials advertising Vitastem and showcasing the product’s versatility. The initial ad presented the product as a household staple for treating minor cuts and scrapes. The next ad in the series will focus on Vitastem’s ability to heal diabetic wounds and major skin conditions. We are in the process of selecting strategic outlets to broadcast the commercials and promote the product to key demographic audiences.
• Prolayed is ready to go. Development has been completed and it is now an official FDA registered product. It will be introduced into the same sales channels as Vitastem as well as other products we will be introducing in the future.
• We have initiated the process of registering Vitastem for medical insurance coverage. The response so far has been very favorable and the expectation is to have final approved for insurance payments and reimbursements for January 2019.
• We are also in discussions with a company that provides services to over 600 Skilled Nursing Facilities in California to use Vitastem in their Wound Care Program.
• Our initial CBD sales of Elixr in Canada was a success and sold out completely. As a result of that success we were recently contacted by a publicly traded Cannabis product company based in Colorado about producing a line of CBD products for sales in the U.S.. We are currently in discussions with them and exploring all options. We are now evaluating our next move with regard to domestic CBD sales as opposed to relaunching a broader campaign in Canada. CBD sales in Canada face far more stringent regulatory obstacles than CBD sales in the U.S. The more favorable logistics of domestic sales vs foreign sales would also increase the bottom line significantly.
In addition to these developments, we are working diligently on many other important initiatives aimed at making our company a major player in our industry. We are constantly seeking out new partners and distributors to keep moving ViaDerma forward and expanding the sales of our products. Admittedly things have not always happened in the timeframes hoped for, but I am confident we are getting very close to moving our Company to the next level. However, as we focus on growing the business we never lose sight of our most important mission to help each and every one of our customers improve their quality of life. Nothing is more gratifying for me then hearing so many success stories from Vitastem users, and how our product has changed their life. That is the reason we get up every morning and continue to fight on so we can make a difference in people’s lives. The more people we can help the more successful we will be as a company and as individual shareholders. Please continue to send us your stories. We love to hear from you.
Sincerely,
Dr. Chris Otiko President and CEO
In VDRM long before me, LOL. I began to load this stock at $.0009 sometime before you started posting on this board, but what merit does that have anyways.
You know as well as I do that this company has been selling shares to expand the business and the dismissed lawsuit depressed the stock price as well, that is why it is oversold.
Once Otiko Pen's a deal and can show revenues, investors will be flooding back in to VDRM.
"If you can't take the heat, get out of the kitchen".
Don't believe us, but it's hard to argue with the results of extensive testing over the years. As a matter of fact, the products works so well KAST would sure like to have Vitastem out of the way so they can sell a similar product.
Why not do a little DD on the product and you will find that the product has a very high efficacy rate of wound healing.
As for the PPS, what a great entry price for anyone looking for a low price stock with a huge potential.
They discount testimony of those who have had positive results with the product and they stand on their own assumptions that the product isn't selling, "Priceless".
$85 a barrel is 2x the revenue reported in the 3/31/2018 annual report. Oil and Gas stocks are going to be "In Favor" for years to come.
Crude oil price is now over $75 a barrel, that alone should move this stock north.
Thank you for sharing your testimony. Vitastem is an amazing product to those who have tried it. Someday this product will get the recognition it deserves and we will all be rewarded handsomely.
Just 90 days ago you asked what a "MM' was, so you tell me, what qualifies you to give stock trading advice?
Same goes for that other character, both of you appear to be the best at spotting a loser stock. Please share with us your wisdom on how you derive at your opinions on stock. ("An Armchair Analyst" if you will).
CEO Otiko made a bold statement when he said that they were close to closing a $3 million dollar deal in three weeks. If this deal comes through, I believe the PPS will run back up to $.02 or better, if not, all bets are off and Otiko will have failed due to lack of creditability.
This trade is about as high of a risk as they come. No risks no reward. The higher the risk, the higher potential for large gains.
The next 3 weeks are not going to be pretty while we wait. I think we shall see some opportunities to add shares.
Good point, but if you take the $3M and divide it by 200k you’ll get $15 per unit. This must be a wholesale price with a quantity discount.
$$$$ Very soon...
"Over the past several weeks I have been meeting with representatives for a South American based distributor. As per our discussions thus far, I expect to receive their initial order for Vitastem within the next few weeks. They have indicated an interest in purchasing lots of 200,000 per month. An order of that size would equal $3 million in annual revenues."
Wow, nice breakout! Come-on $.06, 07, 08, 09, a Dime is in sight.
What's up with VDRM...
LOS ANGELES, March 08, 2018 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink:VDRM), is pleased to provide an update of the Company’s current marketing activities:
1.A/B) ViaDerma is in discussions with a Huntington Beach based international consulting firm, to explore placement of Vitastem in Infomercials, a nationwide pharmacy chain with 9600 stores domestically, and foreign placements throughout the Middle-East and Dubai.
2.) Discussions are also ongoing with representatives from a nationwide pharmaceutical distributor regarding distribution of Vitastem through their affiliated pharmacies and hospitals throughout the US, as well as distribution in the veterinary market though their association with veterinary suppliers nationwide.
3.) ViaDerma is awaiting a formal proposal from CMD Innovations, LLC, to use Vitastem in their wound healing protocol. CMD provides effective medical solutions for healthcare facilities including V.A. Hospitals.
4.) Negotiations are ongoing with a large, regional medical supply sales force for product distribution in pharmacies throughout the Southern United States.
5.) Vitastem is currently undergoing an approval process by government regulatory agencies in Nigeria and the Philippines. Upon approval, Vitastem will be distributed to hospitals in those countries and the Philippines prison system.
6.) Begun the process for approval of Vitastem by Medicare and other insurance companies reimbursement.
ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.
7.) Last month ViaDerma was a proud sponsor at “SB52 Big Game Event” held during Superbowl weekend in Minneapolis, organized by The Brewer Group, a marketing, media and consulting firm founded by former NFL player, Jack Brewer.
Dr. Christopher Otiko, President of ViaDerma, stated, “We are very excited in the direction we are headed with our product distribution efforts. We will provide further updates to these and other initiatives as developments unfold.”
About ViaDerma, Inc.
ViaDerma, Inc. (OTC:VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, visit: www.viadermalicensing.com
Any forecast of future performance is a "forward looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.
Contact information:
Investor Relations
Email: info@viadermalicensing.com
Phone: 310-374-6111
It took awhile but now I got it. Nothing personal Grizzerbear.
Buckled in, locked and loaded for the Bear hunt.